/

NRXP

NRX Pharmaceuticals, Inc.Closed

2.70−0.15 −5.26%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.73 +1.06%

Open

2.85

Prev close

2.85

Day range

2.682.85

52-week range

1.625.06

Volume

551.77K0.65×

Mkt cap

116.90M

P/E ttm

—

Fwd P/E

-7.71

EPS ttm

-0.5800

Div yield

0.00%

Earnings

—

From 52w high

−46.59%

Price Chart

Yahoo Finance · delayed

NRXPOct 13, 2026O 2.85H 2.85L 2.67C 2.70−0.15 (−5.26%)Vol 552.50K

SMA 503.25
SMA 2002.96

1Y change −14.83% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

NRXP NRX Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −8.16%
1 month: −20.59%
3 months: −37.64%
6 months: +8.00%
Year to date: −0.37%
1 year: −13.46%

Valuation & ownership

Market cap: 116.90M
Enterprise value: 90.96M
P/E (ttm): —
Forward P/E: -7.71
PEG ratio: —
Price / book: —
Price / sales (ttm): 34.44
EV / EBITDA: -4.60
EPS (ttm): -0.5800
EPS (forward): -0.3500
Beta (5y monthly): 2.07
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 43.30M
Float: 37.39M
Short % of float: 23.59%
Short ratio (days): 15.10
Held by insiders: 4.12%
Held by institutions: 27.13%
Avg volume (3m): 844.07K
50-day average: 3.26
200-day average: 2.96
52-week change: −13.46%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 28.2
vs 50-day SMA: −17.01%
vs 200-day SMA: −8.70%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.51%
Realised vol (20d, ann.): 36.0%
From 52-week high: −46.59%
From 52-week low: +66.67%

ANR

Analyst Consensus

4 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

38.50

+1,325.93% implied

Low 10.00Median 47.00High 50.00

Recommendation trend

Now4 / 0 / 0
1m ago4 / 0 / 0
2m ago

DES

About NRX Pharmaceuticals, Inc.

Yahoo Finance profile

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.

Sector: Healthcare
Industry: Biotechnology
Employees: 29
Headquarters: Wilmington, DE, United States
Website: nrxpharma.com
Officers: Dr. Jonathan C. Javitt M.D., M.P.H. Co-Founder, Chairman & CEO
Mr. Michael S. Abrams M.B.A.

SEAS

Seasonality · NRXP

2017–2026 · monthly returns

Strongest month Dec +23.39%Weakest month Jun −10.86%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-22.5	-11.4	14.5	39.9	48.3	-7.5	-23.0	10.5	-16.1	-7.5			−0.4%
2025	37.3	-24.8	-9.7	3.4	24.5	23.5	-17.5	-13.8	42.2	-6.1	-21.0	10.6	+23.2%
2024	-19.6	-3.0	31.5	-45.3	47.7	-36.0	-6.1	-18.3	-9.6	-18.9	-4.4	67.9	−52.2%
2023	5.4	-12.8	-35.4	-11.8	20.5	-30.9	-19.4	-24.4	-11.9	25.0	5.8	33.7	−58.6%
2022	-37.9	0.7	-18.1	-36.3	-64.2	7.3	32.2	-18.0	13.8	9.5	77.8	-22.9	−76.8%
2021	140.7	-34.4	-8.0	9.3	-43.2	-47.2	30.6	3.4	-41.0	9.3	-34.1	-28.4	−80.4%
2020	0.8	-0.4	1.1	10.0	-6.6	-5.2	2.1	-0.2	0.3	0.5	0.8	124.5	+130.2%
2019	0.5	0.7	0.1	0.8	0.1	1.1	-0.3	-0.7	1.4	1.2	-1.9	1.0	+3.9%
2018	0.4	0.7	0.3	0.3	0.2	0.4	0.5	-0.5	1.0	0.9	0.2	0.8	+5.4%
2017													—

INSD

Insider Activity · NRXP

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Dec 16, 2024	Javitt Jonathan CChairman of the Board	Purchase at price 1.64 per share.	40K	$65.60K

13F

Investors Holding NRXP

latest 13F filings of 29 followed managers

Investors holding NRXP
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$157.9K	0.00%	38.60K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

NRXP

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

NRXP

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About NRX Pharmaceuticals, Inc.

Seasonality · NRXP

Insider Activity · NRXP

Congress Trades · NRXP

Investors Holding NRXP

Investors Holding NRXP

Congress Trades · NRXP

Insider Activity · NRXP

Seasonality · NRXP

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About NRX Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News